Back

Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

1 September 2019 (11:00 - 11:23)
Organised by:
Congress Presentation Part of: Highlights from the New England Journal of Medicine: editors’ choice European Society of Cardiology ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

2 More presentations in this session

Presentation thumbnail
Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).
Professor J. Mcneil (Melbourne, AU)
Slides Video
Presentation thumbnail
Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.
Doctor M. Mack (Dallas, US)
Slides Video

Access the full session

Session thumbnail
Highlights from the New England Journal of Medicine: editors’ choice

The Event

Event poster

ESC Congress 2019

1 September 2019 11:00 CET
You may be interested in
thumbnail
Webinar
New drugs in the treatment of amyloidosis
16 July 2025
thumbnail
Congress Presentation
Safety and clinical effects of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy
21 May 2023
thumbnail
Congress Presentation
Perspectives on current & future pharmacological treatments of transthyretin amyloid cardiomyopathy (ATTR-CM)
28 August 2023
thumbnail
Congress Presentation
Prognosis changes in patients with transthyretin cardiac amyloidosis after attr-act study.
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources